Results 61 to 70 of about 117,898 (292)

Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor [PDF]

Yeungnam University Journal of Medicine, 2019
Imatinib mesylate is currently used as the first-line treatment for metastatic gastrointestinal stromal tumors (GISTs). Imatinib-induced hepatotoxicity in patients with GIST is very rare.
Min Kyu Kang, Heon Ju Lee, Joon Hyuk Choi   +2 more
doaj   +1 more source

MTSS1 is a critical epigenetically regulated tumor suppressor in CML [PDF]

, 2015
Chronic myeloid leukemia (CML) is driven by malignant stem cells that can persist despite therapy. We have identified Metastasis suppressor 1 (Mtss1/MIM) to be downregulated in hematopoietic stem and progenitor cells from leukemic transgenic SCLtTA/Bcr ...
Braunschweig, T., Brümmendorf, T. H., Chatain, N., Copland, M., Costa, I. G., Gusmao, E. G., Haenzelmann, S., Hamilton, A., Helgason, G.V., Herrmann, O., Holyoake, T. L., Kintsler, S., Koschmieder, S., Li, S., Merle Reher, M., Müller-Tidow, C., Schemionek, M., Schubert, C., Schwab, A.   +18 more
core   +1 more source

Learned Conformational Space and Pharmacophore Into Molecular Foundational Model

Advanced Science, EarlyView.
The Ouroboros model introduces two orthogonal modules within a unified framework that independently learn molecular representations and generate chemical structures. This design enables flexible optimization strategies for each module and faithful structure reconstruction without prompts or noise.
Lin Wang, Yifan Wu, Hao Luo, Minglong Liang, Yihang Zhou, Cheng Chen, Chris Liu, Jun Zhang, Yang Zhang   +8 more
wiley   +1 more source

Role of growth factors in the pathogenesis of tissue fibrosis in systemic sclerosis. [PDF]

, 2010
The most severe clinical and pathologic manifestations of systemic sclerosis (SSc) are the result of a fibrotic process characterized by the excessive and often progressive deposition of collagen and other connective tissue macromolecules in skin and ...
Castro, Susan V., Jimenez, Sergio A., Piera-Velazquez, Sonsoles   +2 more
core   +2 more sources

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Effect of astaxanthin in imatinib mesylate-induced cardiotoxicity

Acta Medica Alanya, 2020
Aim: Imatinib mesylate is a tyrosine kinase inhibitor and is approved as a standard first-line therapy of chronic myeloid leukemia. Oxidative stress, as well as intracellular calcium overload and mitochondrial dysfunction, play an important role in ...
İshak Suat Övey, Can Ramazan Öncel
doaj  

A Study of the Identification, Fragmentation Mode and Metabolic Pathways of Imatinib in Rats Using UHPLC-Q-TOF-MS/MS

Journal of Analytical Methods in Chemistry, 2021
In this study, The metabolites, metabolic pathways, and metabolic fragmentation mode of a tyrosine kinase inhibitor- (TKI-) imatinib in rats were investigated.
Sijiang Liu, Zhaojin Yu
doaj   +1 more source

Clinical Implication of Targeting of Cancer Stem Cells [PDF]

, 2012
The existence of cancer stem cells (CSCs) is receiving increasing interest particularly due to its potential ability to enter clinical routine. Rapid advances in the CSC field have provided evidence for the development of more reliable anticancer ...
Al-Hajj M, Bao S, Bardsley MR, Barlogie B, Bentzen SM, Bertout JA, Blazek ER, Bruns CJ, Brunsvig PF, C.J. Bruns, Cao X, Chen MS, Clayton S, Collins AT, Cortes J, Costello R, Dalerba P, Diehn M, Dou J, Dylla SJ, Eyler CE, Fischer S, Garvalov BK, Ghiaur G, Gibbs CP, Gilbert CA, H. Niess, Haferlach T, Hochhaus A, Hosen N, Huff CA, Hurwitz H, Jiang X, Jones RJ, Jones RJ, Jones RJ, Ju Z, K.-W. Jauch, Kanamori M, Kiladjian JJ, Klonisch T, Kojima T, Korpal M, L. Zhao, Li C, Liu G, Liu R, Liu S, Lonardo E, Mauro MJ, McDermott SP, Merante S, Mimeault M, Moserle L, O’Brien SG, Park CY, Phillips TM, Platet N, Q. Bao, Rasheed ZA, Reya T, Reya T, Richardson GD, Roeder I, Seidel S, Singh A, Singh SK, Strojnik T, Stupp R, Suh MR, Szotek PP, Tang C, Tang M, Todaro M, Tu LC, Vermeulen L, Wilson BJ, Wright MH, Xu N, Y. Zhao, Yu F, Zhao C, Zhou BB   +82 more
core   +1 more source

Breaking Barriers: Characterization of the Intradermal Lipopolysaccharide Challenge as an In Vivo Model for Controlled Induction of Vascular Leakage in Healthy Volunteers

Clinical Pharmacology &Therapeutics, EarlyView.
Vascular leakage and its associated phenomena vasodilation and endothelial activation are pathophysiological features of various diseases. Multiple drug candidates targeting these phenomena are in development, necessitating translational models to demonstrate proof‐of‐pharmacology and proof‐of‐mechanism in early‐phase clinical trials.
Marella Cornelia Elizabeth van Ruissen, Menno van Diemen, Liza Botros, Ingrid Tomljanovic, Hind Achbo, Dimitra Eleftheriou, Paul Willem Schenk, Naomi Bertine Klarenbeek, Derek William Gilroy, Manon Aleida Adriana Jansen, Matthijs Moerland   +10 more
wiley   +1 more source

Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model [PDF]

, 2015
Cytoreductive surgery combined with intraperitoneal chemotherapy (IPC) is currently the standard treatment for selected patients with peritoneal carcinomatosis of colorectal cancer.
Ceelen, Wim, De Wever, Olivier, Descamps, Benedicte, Gremonprez, Félix, Izmer, Andrei, Vanhaecke, Frank, Vanhove, Christian   +6 more
core   +4 more sources